FORA Capital LLC Buys New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA)

FORA Capital LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 41,547 shares of the biotechnology company’s stock, valued at approximately $831,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth about $29,000. Hollencrest Capital Management purchased a new position in ADMA Biologics during the third quarter worth approximately $30,000. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at $31,000. Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at $62,000. Finally, CWM LLC grew its stake in shares of ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after buying an additional 4,367 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analyst Weigh In

ADMA has been the subject of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James boosted their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 5.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Price Performance

ADMA stock opened at $21.83 on Friday. The firm has a market cap of $5.16 billion, a P/E ratio of 77.96 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a 1 year low of $3.60 and a 1 year high of $23.64. The stock has a 50-day simple moving average of $19.08 and a 200-day simple moving average of $15.23.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the company earned $0.01 earnings per share. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.